NO327097B1 - Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer - Google Patents

Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer Download PDF

Info

Publication number
NO327097B1
NO327097B1 NO20041891A NO20041891A NO327097B1 NO 327097 B1 NO327097 B1 NO 327097B1 NO 20041891 A NO20041891 A NO 20041891A NO 20041891 A NO20041891 A NO 20041891A NO 327097 B1 NO327097 B1 NO 327097B1
Authority
NO
Norway
Prior art keywords
monocyclic
bicyclic
alkyl
tricyclic
heterocycle
Prior art date
Application number
NO20041891A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041891L (no
Inventor
Eddy Jean Edgard Freyne
Jean Fernand Armand Lacrampe
Werner Constant Johan Embrechts
Marc Willems
Peter Jacobus Johannes Antonius Buijnsters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20041891L publication Critical patent/NO20041891L/no
Publication of NO327097B1 publication Critical patent/NO327097B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
NO20041891A 2001-11-01 2004-05-07 Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer NO327097B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204193 2001-11-01
PCT/EP2002/012067 WO2003037869A1 (en) 2001-11-01 2002-10-29 Amide derivatives as glycogen synthase kinase 3-beta inhibitors

Publications (2)

Publication Number Publication Date
NO20041891L NO20041891L (no) 2004-05-07
NO327097B1 true NO327097B1 (no) 2009-04-20

Family

ID=8181176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041891A NO327097B1 (no) 2001-11-01 2004-05-07 Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer

Country Status (21)

Country Link
US (1) US7183288B2 (da)
EP (1) EP1442019B8 (da)
JP (1) JP2005507419A (da)
KR (1) KR20050040814A (da)
CN (1) CN1582277A (da)
AT (1) ATE375331T1 (da)
AU (1) AU2002363174B2 (da)
BR (1) BR0213791A (da)
CA (1) CA2463821A1 (da)
DE (1) DE60222921T2 (da)
DK (1) DK1442019T3 (da)
EA (1) EA007578B1 (da)
ES (1) ES2294190T3 (da)
HU (1) HUP0402330A3 (da)
IL (1) IL161661A0 (da)
MX (1) MXPA04004177A (da)
NO (1) NO327097B1 (da)
NZ (1) NZ531855A (da)
PL (1) PL368917A1 (da)
PT (1) PT1442019E (da)
WO (1) WO2003037869A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1738797A (zh) 2002-11-19 2006-02-22 阿基里昂药品公司 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
AU2005230902A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3-receptor ligands
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
EP1763526B1 (en) 2004-06-28 2009-06-24 Bayer Schering Pharma AG 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
JP2009520811A (ja) * 2005-12-22 2009-05-28 クリスタルジェノミクス、インコーポレイテッド プロテインキナーゼ活性を阻害するアミノピリミジン誘導体、及びその製造方法並びにこれを有効成分として含む医薬組成物
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EA015555B1 (ru) 2006-05-30 2011-08-30 Янссен Фармацевтика Н.В. Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
JP2009538933A (ja) * 2006-05-31 2009-11-12 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての化合物およびその使用
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2681586A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2160393A1 (en) * 2007-05-18 2010-03-10 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
EA018582B1 (ru) 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
FR2931108B1 (fr) * 2008-05-15 2011-01-07 Peugeot Citroen Automobiles Sa Limiteur de vitesse a indicateur de vitesse limite a deplacement manuel, pour vehicule automobile
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2334646A2 (en) * 2008-09-16 2011-06-22 Abbott Laboratories Substituted benzamides as cannabinoid receptor ligands
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TWI600638B (zh) 2010-01-22 2017-10-01 艾斯特隆製藥公司 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
BR112013011868A2 (pt) 2010-11-16 2016-08-23 Acetylon Pharmaceuticals Inc compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103804362A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2929576T3 (es) 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
WO2015054474A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
CR20160308A (es) 2013-12-03 2016-11-08 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
AR105812A1 (es) 2015-06-08 2017-11-15 Acetylon Pharmaceuticals Inc Métodos para la preparación de inhibidores de proteína deacetilasa
AR104935A1 (es) 2015-06-08 2017-08-23 Acetylon Pharmaceuticals Inc Formas cristalinas de un inhibidor de histona deacetilasa
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
US11324744B2 (en) 2016-08-08 2022-05-10 Acetylon Pharmaceuticals Inc. Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN110128305A (zh) * 2019-05-10 2019-08-16 天津大学 二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途
CN116813497B (zh) * 2023-08-31 2023-11-14 天津匠新致成科技有限公司 一种酰胺类化合物及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1198551A (en) * 1968-01-22 1970-07-15 Union Pharma Scient Appl New Nicotinuric Acid Derivatives
DE2334266A1 (de) * 1972-07-07 1974-01-31 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidin-2,4 (1h, 3h)-dione
JPS5069096A (da) * 1973-10-25 1975-06-09
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU1507199A (en) * 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
CZ299380B6 (cs) 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
KR100581199B1 (ko) * 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
HRP20080359B1 (hr) 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek

Also Published As

Publication number Publication date
KR20050040814A (ko) 2005-05-03
JP2005507419A (ja) 2005-03-17
DE60222921D1 (de) 2007-11-22
NZ531855A (en) 2005-12-23
AU2002363174B2 (en) 2008-09-25
EA200400615A1 (ru) 2004-08-26
EA007578B1 (ru) 2006-12-29
NO20041891L (no) 2004-05-07
PT1442019E (pt) 2007-12-11
EP1442019B8 (en) 2013-10-30
CN1582277A (zh) 2005-02-16
DK1442019T3 (da) 2008-01-14
CA2463821A1 (en) 2003-05-08
HUP0402330A2 (hu) 2005-02-28
US7183288B2 (en) 2007-02-27
DE60222921T2 (de) 2008-08-07
EP1442019B1 (en) 2007-10-10
ES2294190T3 (es) 2008-04-01
BR0213791A (pt) 2004-12-07
MXPA04004177A (es) 2004-09-06
ATE375331T1 (de) 2007-10-15
EP1442019A1 (en) 2004-08-04
PL368917A1 (en) 2005-04-04
HUP0402330A3 (en) 2010-03-29
WO2003037869A1 (en) 2003-05-08
US20050176713A1 (en) 2005-08-11
IL161661A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
NO327097B1 (no) Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer
NO326889B1 (no) Aminobenzamidderivater som glykogensyntase-kinase 3beta-inhibitorer
CN100491371C (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
AU2002363174A1 (en) Amide derivatives as glycogen synthase kinase 3-beta inhibitors
AU2002363176A1 (en) Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
AU2002363177A1 (en) Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors
JP2010520887A (ja) 蛋白キナーゼの阻害剤として有用なアミノピリジン
JP2007505888A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2018531266A (ja) ピリドン誘導体およびキナーゼ阻害剤としてのその使用
JP2018531266A6 (ja) ピリドン誘導体およびキナーゼ阻害剤としてのその使用
EP3853225B1 (en) N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer
NZ543748A (en) Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors)
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
HK1178149B (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees